Clinical Study
Interferon Alpha Association with Neuromyelitis Optica
Table 2
Clinical characteristics of neuromyelitis optica (NMO) and multiple sclerosis (MS) patients with detectable interferon-alpha.
| | Clinical characteristics | NMO | MS |
| | Females | 5 | 2 | | Age of onset: median (range) | 36 (20–64) | 27 (25–29) | | Duration of disease: median (range), year | 7.9 (2–20) | 6.5 (2–18) | | Positive anti-aquaporin-4 antibody | 5 | 0 | | EDSS; median (range) | 7.5 (5–9) | 4.5 (4–5) | | Acute relapse at investigation time | 7 | 1 | | ≥3 vertebral segments spinal cord lesion | 9 | 0 | | Optic neuritis | 9 | 1 | | Brainstem syndrome | 6 | 1 | | Treatment | 7 | 2 | | Interferon beta | 1 | 1 | | Natalizumab | 4 | 1 | | Azathioprine | 1 | 0 | | Rituximab | 1 | 0 |
|
|
